REMARKS

The present application had claims 18-21 pending. Applicant has amended claims 18 and 21. Thus, claims 18-21 are currently pending. Applicants request that the pending claims be reconsidered.

Drawings

The Examiner advises that since the sequence listings will be published as part of the patent, and in order to reduce redundancy, any Figures which consist only of nucleic acid or protein sequences that have been submitted as sequence listings should be deleted. The Examiner specifically suggested the deletion of Figures 1, 2, 3b, 4b, 5b, 6b, 9b, 10b, and 11b. Applicant has amended the drawings to delete the listed Figures. No new matter has been added by the amendments. Further, Applicant has renumbered the remaining Figures as indicated in the Amendments to Drawings section of this Response. Also, Applicant has amended the specification to remove references to the Figures which have been deleted from the application and update the Figure numbers for the remaining Figures which have been renumbered. Accordingly, Applicants respectfully request that the objection be reconsidered and withdrawn.

Title

The Examiner states that the title of the invention is not descriptive. Applicant has amended the title of the invention to that suggested by the Examiner. Accordingly, Applicants respectfully request that the objection be reconsidered and withdrawn.

Rejections under 35 U.S.C. § 101

The Examiner rejected claims 18-21 under 35 U.S.C. § 101 because the claimed invention allegedly is not supported by a specific, substantial, and credible asserted utility or a well established utility. Applicant directs Examiner's attention to pages 27-28 and page 33, lines 3-6, which identify the homology to known Arrestin. Applicant directs Examiner's attention to Examples 2-5 on pages 42-45 of the specification as originally filed. Within those positions in the specification, and within the references cited therein, Applicant asserts specific and substantial utility for the claimed invention, and the well-established utility thereof. Examiner correctly states that SEQ ID NO 2 has homology to known Arrestins. Based upon Applicant's disclosure and the Examiner's search, there is no reason to doubt the assertion that SEQ ID NO 2 encodes Arrestin. Further, Arrestins have a well-established use in biology based upon the protein's ability to participate in the olfaction cascade.

In paragraph 16, the Examiner states that the asserted utility is not substantial. However, to be substantial, a utility needs only to define a "real world" use. M.P.E.P. § 2107.01. Here, the claimed polypeptide has homology to a known and well-established class of proteins, and the claimed polypeptide may be used in an assay to identify compounds which interfere with the olfaction cascade. It is noteworthy that the Examiner acknowledges in paragraph 12, second sentence, that the asserted utility is <u>credible</u>. Per M.P.E.P. § 2107.01 III, "if the asserted utility is <u>credible</u>, there is no basis to challenge such a claim on the basis that it lacks utility under 35 U.S.C. 101." Further, since a reasonable correlation between the activity in question and the asserted utility exists, no further confirmation of the properties of the protein or conclusive evidence of operativeness are necessary to meet the threshold of utility. See M.P.E.P. § 2107.03 and § 2107.01

III and cases cited therein. Accordingly, there is a well-established utility associated with the claimed invention. Thus, Applicant respectfully requests that the rejection be reconsidered and withdrawn.

Rejections under 35 U.S.C. § 112

The Examiner rejected claims 18-21 under 35 U.S.C. § 112, first paragraph. Applicant has amended claims 18 and 21. No new matter has been added by the amendments. Support for the amendments is found at least on page 30 of the specification. Applicant has amended claims 18 and 21 to further clarify the claim scope. With reference to paragraph 18 of the Office Action, Applicant believes the claimed invention is supported by a well established utility for the reasons set forth above. With reference to paragraphs 19-28 of the Office Action, Examiner's previous interpretation of the scope of claims 18-21 was overly broad. Applicant, as noted in the currently amended claims, is claiming "an amino acid sequence of which comprises at least 40 consecutive residues of SEQ ID NO: 2." Stated another way, such claim language includes any polypeptide having at least 40 consecutive residues of SEQ ID NO: 2. Such claim language does not include "any polypeptide that is at least 20 residues long and comprises as few as one amino acid residue of SEQ ID NO: 2" as suggested by the Examiner in paragraph 20. Such an interpretation would include any polypeptide that is at least 20 residues long and includes any one of the amino acids present in SEQ ID NO:2. Applicant believes that the Examiner's overly broad interpretation of the claims resulted in an overly broad claim scope which resulted in rejections under 35 U.S.C. § 112, first paragraph. Applicant believes that the specification supports the currently pending claims. Accordingly, Applicant respectfully requests that the rejections be reconsidered and withdrawn.

With reference to paragraphs 22-28 of the Office Action, the current specification certainly provides a disclosure that would allow the skilled artisan to practice the claimed invention without undue experimentation and provides a written description of the claimed invention. Applicants direct the Examiner's attention to pages 24-32 of the specification, in addition to the remainder of the specification, to obtain information regarding how to make and use the currently claimed invention, as currently amended. Further, specific guidance with regard to conservatively modified amino acids is provided on pages 30 and 31. Accordingly, Applicant respectfully requests that the rejections be reconsidered and withdrawn.

Rejections under 35 U.S.C. § 102(b)

The Examiner rejected claims 18 and 21 under 35 U.S.C. § 102(b) as allegedly being anticipated by Hyde et al. Applicants have amended claims 18 and 21. No new matter has been added by the amendment. Support for the amendment is found at least on page 30 of the specification. Pursuant to M.P.E.P. § 2131, and case law therein, a claim is anticipated when each and every element of the claim is found in a single prior art reference. Hyde et al. does not provide all of the limitations of the amended claims. Thus, Applicant respectfully requests that the rejections be reconsidered and withdrawn.

Applicant has merely commented upon certain aspects of the invention and reserve the right to provide further comments as necessary. Applicant notes that these remarks should not create limitations to the claims and that the claim language itself should be considered.

Should the Examiner feel that a telephone conference with Applicant's attorney would advance the prosecution of the application, he is invited to call the undersigned at 901-537-1049.

The Commissioner is authorized to charge any deficiency or credit any overpayment associated with the filing of this Response to Deposit Account 502346.

Respectfully submitted,

Douglas W. Schelling, Ph.D.

Registration No. 48,335

WYATT, TARRANT & COMBS, LLP 1715 Aaron Brenner Drive, Suite 800

Memphis, Tennessee 38120-4367

Telephone:

(901) 537-1049

Facsimile:

(901) 537-1010

Should additional fees be necessary in connection with the filing of this paper, or any future papers, or if a petition for extension of time is required for timely acceptance of same, the Commissioner is hereby authorized to charge Deposit Account No 502346 for any such fees; and applicant hereby petitions for any needed extension of time.



CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this Response and Amendment, including Certificate of First Class Mailing (13 pages), Extension of time to reply (2 pages, one original and one copy), Replacement and Annotated Drawings (37 pages) and a self addressed return post card are being deposited with the United States Postal Service, postage prepaid, as first class mail in an envelope addressed to:

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Douglas W. Schelling

Signatur

Date

APPLICATION NO. 10/056,405 DOCKET NO. N7841

Amendments to the Drawings:

The attached sheets of drawings include the deletion of several Figures and the renumbering of

the remaining Figures. These sheets replace the original sheets including Figures 1-11. Figures

1, 2, 3b, 4b, 5b, 6b, 9b, 10b, and 11b have been deleted. The remaining Figures have been

renumbered as follows: 3a to 1, 4a to 2, 5a to 3, 6a to 4, 7 to 5, 8 to 6, 9a to 7, 10a to 8, and 11a

to 9. Regarding previous Figure 8, renumbered as Figure 6, the right hand column providing

references to the deleted Figures has been removed.

Attachment:

Replacement Sheet

Annotated Sheet showing changes



Figure 1) Renumber (june

Anopheles gambiae odorant receptor 1 genomic sequence (SEQ ID NO: 9)

5

Features:

- 1) Presumed Untranslated 5' and 3' regions are <u>underlined</u>.
- 2) Potential TATA box transcription initiation signal is <u>double underlined</u>.
- 10 3) Putative Start (ATG) and Stop (TAA) codons are in BOLD.
 - 4) Introns are tentatively assigned and are shown in lower case. Exons are highlighted.

AGCTTTGTTCATTTATGTTGAAATCTAGCCCATTTTGTATAGTGCTGAACGACGAAGAACATACGAAAGTACCTCGT 15 $\tt CCGAACACTATCAACATTAATTATACCAAGCTAGAAGAAGATATTTATAGTCAAGCCTCAACATCATAGGAAACTTT$ AGCAAAACCATTTAATTTACATGATGATAAGTCCCACCTCTTACCCCAGCACAGGTTTGAGAAGGACGAAAGTATCT TTACGATAATATTACTCTAAGGTAGTTTTTGAATAAAATAAAAATTTACGTGCAAGTGGTGGCATCGGACATCATTC GAACACGTCAGGACATAACTGCGACATGCGTATGGTCAGTTCCACTAGTGCCAACACTGGTTCCAGGGCACTACCTT 20 $\underline{\tt CCGAAGCAGTAGAACCTAATGTATTGGAAATTATTAGGACATACTGCAACATGCATATGGCTAGTTCCGCTGGTACC}$ <u>AACGATGGCACCAGGACACTATCTGCGGCCTTGTAAAATCACTGTAAAATCTATACAAAAACGGCTTT</u>ACCCAT<u>A</u>CT TTATCACAAAAACGGCAGGTGAGGGCTGGATTGCTTCAAAGCATTAGAA<u>ATATATA</u>ATTTCAAAGTCCATAATCTCC AATGCTCAATTGTTGTAGATTCGTTGGATGACTCTCGCTACGTGCTATAGTGGTCAATACTTCCAATTAGATTTCAT 25 AATTAGTTTCCAATTGTCCACGGAAAACCCaCAAAAGAAAAAAAACTTGTATCTAGGGTGGAATTTTTCGAGAACA aacatttaaaactgataattaagatgagtaattgcttcgtcatcacctaagaaatcgattagtttggataaaaagaa 30 aattcctcgttgaaaattggtctcctatagttctgctaacgggccacttcaaaagcaagaactaacaaaatcataat tatggtgcaagtaactatcagtaccagtaatcgccattaaaaacttttcctcaattttgcggctcgttaccggctaaa tacagagcagagtaacgggaagtgatcaacgtcgctattagtataacgaggaacgccctccgaaggtgtgttgaagg accttttcaaattqaaaccaaqtactqtttccaqttttaaattqqataqttataaaatgaqccgttcaacgatcggg catcatttgagtttcatcttcgaggagaaatagatcagtgccactgtttaaccgaaagtaatgaagctgaacaaact 35 EGCCACCCCAACATIACCCCATICACCCAACCCCCAACCCCCAACCCCTACCCCTTACGCCTTTCCCCCTTTCCCCCATICATCTTACCTA CANCTENAGGCTCTVAAGGCCAAGGCCCTATACTTCAAGGATCTGAAGGATATTAAATG HOATICTVACIAACCTRECHAAAAACHTTRAACTPACAAACGAACCCAATRICACCCTRICHRCRCRCCCCAACCTTRAAACTC 40 <u> ERGIVATCACCCCAAACAACCACCAACAAUTECAC</u>gtaagcctgctgggaaatatgactaaaaagagtgctaacaaacga ctctcctccaaatgtag@cccGrTTTACAATG&AGE&AGE&AGEGTFTTTEGGT&AT&AGETTTCTCAT& CCCRCCACTARCACCATRCCCACATACRCTACCCRCTACRCTRCCTCRARCAACCATRCCAARCCATRCCACACACCCCC ACCHACA ACTRICT CCACCCATA COARICT THACCCCCT TEATECTA ACACAMA AT CCACAA AT THE TECCCCT TO THA 45 ttatcag ettegacatgaggiiggetegaaaggecaattggiiggaaggeaatgegaaagaaaaaaa SCANCEACCANCACTICEAAAAGITENACEGHACEATTENACETTAAAAGITAACEGACTTETTENEETETTETHTEAAFAACEGAC ETAACgtacgaattgggccaattaattgtgtcatttaaaaagcttgacccaacttttcacagcttcggcgatgaagt qcaqqacattttccaaq@ATCIATCITCCCCCAACIATCCCCCHCTGIAAITAICATIT 50 œcoccanicnanaccanic coccanicnectere contrate de la langua de la company de la company de la company de la comp ####C#C##ACC#ACCAAWCAAWCTCC#AWACCgtaggttggacacgtagaggaattaaatgtttgggaagaata tcaataccaaatagtatgatgtttcgttacagACCCATAAATTTACACACACTTTCCCGGTTTTCCAACTACTTCAAC <u>ITICCATAACCCTACCAACCAACCAATCATATTITTTCTCCAAATI</u>gtgagatagcggtgtatttgtgcagtcagtaca

	ttaaatacgttctctatttcag <mark>eACFCT#AAAGA#GTFCA@ANGAACGFGCGAAGFGFCT#GAACGFFAAGCCFFAAAT</mark>
5	CTRCACACACATITITICCAC gtatgtaattatgctgtggtatttagcttgaaataagctacaaactttgaaagtaattt
	caatctgttttgtagayyvayveaxacvayveenxacvecvayvevaeeeeeevacvacaacaacaacaxveexacxaveexavexavaxaveeee
	ETANIATECE DAN TGTTGAAATTATATTTTGTTAGATTTATTGCATAAAGTAATATTTAATTTTATACATCAAACGT
	AAGCCCGCtaGTTTTCAATTAGCCTTTTCCAAAATTTATCAAATTGATTTCGAATTGATTG
	TAATCTGATAGGATATCTTGTTTATCCAATAGAGGTGTGGAAGCGTTCCCAAGCCATTCGTTTGATAGTTTATAGCA
	${\tt CCGTCGAGCAGTTGATCGCTGATCGCTAGGCGCACCTGATTTTATCTTTATCTCGCACCTGTTATGGCAAGGGCGCGCGC$
	$\tt CTTTTCACACGTTTCACACAATATAATGCACATGTATAATGCATTCTTACTTTAGCATTTTTGTTACATATAATACC$
	AAAATTATGCATTTTTATTCTCACGCAACGATTAGAGGATGACTTCACAAAGGTCCATCTAGTGGTAGGAGGTATAC
	AATTATACCTCTCAAAATCTCACAGCALAATGAGAAACAAAAGGATACCAAGCATACCCTTTTTTTACTTGACAATT
	TCATTTGATTTATGTAATAAGCACTGCaCGTCGACTTCCTAAAA

Figure 1 continued

Renumber 4: 9012 15

Figure 2 Lennber figure

Anopheles gambiae odorant receptor 2 genomic sequence (SEQ ID NO: 10)

5

Features:

- 1) Presumed Untranslated 5' and 3' regions are underlined.
- 2) Potential TATA box transcription initiation signal is double underlined.
- 10 3) Putative Start (ATG) and Stop (TAA) codons are in BOLD.
 - 4) Introns are tentatively assigned and are shown in lower case.
 - 5) Exons are highlighted.

	${\tt GGGATCCTCTAGAGTCGACCTGCAGGCATGCAAGCTTCCCTCACCGTGACGTGCTAGAAATGGTTCAACATACTCGT}$
15	CCGGCAGAGCGAAGACGACGAACAGCGGAATGTCCCAGGAAATGTAATGAGATATCACAGCAAGTGAACCCAAACCG
	AGCTGTGCGCTTTGTGTTGCGCTTTAAAAATGGCCCTTCCTT
	AAATCCACTGACCACTGGCCACACATCAACCACCGGAGCGGAGCCTCAGTGCCCAGCGAAGC <u>ATATAA</u> TTTGCTCA
	AAAAGTCACGGTACTCAATTAATTTGATTATAATCAATTTCGTGGCTTCCAACACCCCTTCTTCCACAATCCATCG
	CCGAGTGAGCGAGTATAAAGGTGAAGAAACGTACCTTGCGCTTGCTCACTAACTGAACCGGATTTCAAAAAGGAACA
20	TAAACCGCAACCCACAGCCGAAAATGCTGATCGAAGAGTGTCCGATAATTGGTCTCAATGTGCGAGTGTGGCTGTTC
	RECUREDANCE GEORGE GEORGE GETTEN COORTEN DE COORTEN DE COORTE DE C
	CHTICCTCAACCTCTACHCCTGGGGGCGACATGAGCGAGCTCATCATCAACGCATACTTIAACCCHCCTCTAACTTIA
	ACCRECATE tacgtgggcgaggggaggggcaataaccttcccacttggtggatattttcataccttttccatgtgtt
	ttttattctctgtttgttgccatccag@TCCGAAGCTCCTTTCTCGTGATCAATCGACGGAAATTTGAGACATTTT
25	TTGAAGGGGTTGGGGGGGAGNAGGGTGTGGAGGAGgtaagtcattggtttttctagtttttgggggagttgtttaca
	ccataaccaccccgacggtaacatttgatcgtcccgcgaaaatgtttgtacagAAAAATGAGGAGAGGGGGGGG
	GCTGCACCCCTACACACACCCCCCCCCACCCATCCTATICCATATICCATATICCATATICTCCCCCCCC
	HIGHEYCCHANGCRCHEHT RENGCCGGGGGGGGGRAGGGRAGGGCGGGGAGGAAAACCGGGGGGGAGGAAGAA
	AGGGGGAGGTVACCAGGTGGTTTTTTGTTGGTAGGTTTTTTAGGTTTVAGGTTTVGGGGGGGG
30	<u>execution voccesse en concentratione caracterises en conversión de conversión de confeces de confeces en constantes de conversión de confeces de conf</u>
	GCCACACGCCCACCATECCCATICCCACCCCCACACACGCCCCCACCACACACGCCCCACCCTCCAACCATICTCCAAAACCTAAAACCTAAAACCTAAAACCTAAAACC
	CACAAACAAATCATCCAC
	atttcgggatgcggcagcacgcatacacacaaaccggaagccattaattctcccgttttcatgcccgcacgggcact
	gggtcatgtttcacatccttcctttccaaacacacacacgcgcgtgcacgtacagAvAvChycAvCAvCvC
35	MACTICACTICENCACCCANCTENCTCTCTCTCCACCTTTCCTCTTCCTCTTTCCTCACTTCCTCATCCTTCATCCTCACTCCTC
	AAGCATEG taagtaaaatcgaccgacgtgcggtcgctagtccgtctccggactctcatttcgggactcaatcgttcc
	atctctcaatag <mark>k@dxxxi@x@cii@@dxCxGxxi@xyxxxi@xyvxi@ciix@ciix@xx@xii@xii@xxicii@@dx@xxidii</mark> i
	IGGGTTGIANTIGGGCANGGANGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG
4.0	tagatcggctgtcttacattgttgtgtttctgcatggggatcggttttgtttttcctctccatttcagAGCCTAGGC
4 0	ĬŖĿĬĬĠĠĠ <mark>ĠŶŔŀĠĠĠ</mark> ŶſĸĬĿĥŶĠ ŶŷĸĬĠĠ ŶĠĠĠŀſĠĠĠĠĠĠŶĠŀĿĬĸſĠŶĠĠŖĸĸŶĠĠĠŶŔĸŶŶĠĠĸĸĸŶŊĠĠĠĸĸŖĠŶŖĸĸĠĸŖĸĸŖĸĸĸĸĸĸĸ
	NGCHGGNONGGCNCCCANCCCRCCHNNCLtttggctgatcgatgctctgttcaatgaacatggcacagaaggctgtgta
	aatagctgttcattaataagttttttcagaatgtatcgtttttagttgatttaaacgcattgttctatgcaatggta
	gcaacaatagaccgcctttattaatccaagcttcctttaggattgatt
4 ==	tagtaaccaatttagttacaggaaccaaaatacagaatttattattattattattattattattattattatt
45	ttattattattattattattattattattattattatta
	attattattattattattattattattattattattatt
	tattattattattattattattattattattattattat
	ttattattattattattattataacaataattattattat
F0	attattattattattattattattattattattattatt
50	ttattattattattattattattattattattattatta
	attattattattattattattattattattattattatt
	ttattattattattgctattgttattattcttattattgctattgttattattattattcttattattgttgtt
	gttgttgttcttattattgttgttgttattcttattattgtttattattattgtttttttt

acaataatctctaagaattaaaattgcattttgtaatgaaatatgttgattgttcgaatagttcagaaaaacttaaa aatgcctcagcattaaacagttttgaggttgttcagggcatttagtttagatattttagtattttaaagcatttgtt ttcattactacaaaaaagcaaatttatgagtgaattactttcagttcttctaaacgcctatgtgtatgcaattacat aacaataqctctcttttttattqcatttttccttaqtaatctaaatccaatctcttctttccctcttqcaqATTAAA ETCGCCAACCTCTACCCCATGACCTTGCAAAATCTTTCAAAAATTGCTCAACGTGTCCTACTCCTATTTCACACTGCT GATCATCAAACACCATTAGCAGCCACAAAGTTACCAGCCGCTTATCCCACGGGATTTGGTGGAAAGTTATTGCACTG GCGACGGTGAAAAAACGCTGCATTATTGTGCTTGCTTCAGCATTCCAGCGAATGACTCTTAAACTTTTCCATTCAAA AGTCGCGATGCTCACGATACGGAGCGGTGTGTTGTTCGATCCGCCGAGTGCACTCGCAAGCCGGTGATGTTGCCGGT AAGGTCTCTGCTCCGGGGCATGGATTCTTTCCCCCTCCGGGTGGTTGGGGGGTATTGTTTAGGTTTTTATTTTACAAA ACGAACATGGCCAACAAACACAGCTTCTATCTCATCTCTGTGTCGCACTGTCTCGCTTTCCCGCTGCGTTGCTTGTA GTACTATCATTGTTTTAGTCCACGGGTTTACTTCTAATTCCATTGCACCACGCAAAAAGGCTCATCCTTTGCTCGTT GCTGTGTGCGCTCGAGTCAGCCGACGGTACAAGGTTTAACCGGTACAAGCAACTCCCGGACCGATCCCAAAACTCTG AAGAGCGAGAAACATTGGTACGATTTGGTGTGTTAGCAAATTTGATTTCCACTGATTTTGAGTGCAAATTTAATGC ATCGAAAATTTGCCATTCAGGGTAAAGTTGCTCGTGGACGGATCCCCCGGGCTGCAGGAATTCGATATCAAGCTTAT $\tt CGATACCGTCGACCTCGAGGGGGGGCCCGGTACCCAGCTTTTGTTCCCT\underline{TTAGTGGA}$

5

10

15

20

25

30

Figure 2) continued

Renumber figure

Figure 3 - Renumber figure

Anopheles gambiae odorant receptor 3 genomic sequence (SEQ ID NO: 11)

5

Features:

- 1) Presumed Untranslated 5' and 3' regions are underlined.
- 2) Putative Start (ATG) and Stop (TAA) codons are in BOLD.
- 3) Introns are tentatively assigned and are shown in lower case.
- 10 4) Exons are highlighted.

AAGCAGAACACATCAAGAAGCAATTAGGTGTGTCGTACGTTAGCAAGTAGTTCGCGAGGAGGAATAAAATAG**ATG**EC TTCTGAGCGGCTTCGTCTCATTACTTCCTTCGGAACTCCTCAAGACAACGCACGATGGTACTGCCAAAATTAAAGG ATGAAACAGCAGTGATGCCGTTTCTGCTGCAAATTCAAACCATTGCCGGACTGTGGGGTGACCGTTCCCAGCGGTAC CGTTTTTATCTCATCTTTTCCTACTTCTGCGCGATGGTGGTTCTACCCAAAGTGCTGTTCGGTTATCCAGATCTCGA 15 GGTTGCGGTACGCGGCACGGCCGAGCTGATGTTCGAATCGAACGCATTCTTCGGCATGCTAATGTTTTCCTTTCAAC GCGACAACTACGAGCGATTGGTGCATCAGCTGCAGGATCTGGCAGCTCTAGGtgagtatgcagccaatcgattgttc caaaccttcqcaacatccttcqtaacactqctacactttcaqTCCTCCAAGACCTACCCACAGAGCTGGGAGAGTAC CTGATCTCAGTGAACCGACGGGTCGATCGGTTCTCCAAAATTTACTGCTGCTGTCACTTTTCCATGGCAACGTTCTT 20 TTGGTTCATGCCCGTCTGGACGACCTATTCCGCCTACTTTGCTGTGCGCAACAGCACGGAACCGGTCGAGCACGTGT TGCACCTCGAGGAAGAGCTGTACTTCCTGAACATTCGGACTTCGATGGCGCACTATACGTTTTATGTGGCCATTATG TGGCCCACGATCTATACGCTCGGGTTTACCGGTGGCACAAAGCTGCTGACCATTTTCAGCAATGTTAAGTACTGTTC GGCCATGCTGAAGCTCGTTGCACTCCGAATCCACTGTCTAGCGAGAGTAGCGCAAGACCGAGCGGAAAAGGAGCTGA ACGAGATTATTTCCATGCATCAGCGGGTACTCAAgtaagtaaattcaaattgaaagttttgcagggaataacttgag 25 tgtgtctgacccgtgcacatcctagCTGCGTGTTCCTGCTGGAGACGACATTCCGCTGGGTATTTTTCGTGCAGTTC ATTCAGTGTACAATGATCTGGTGCAGTCTCATCCTCTACATAGCGGTGACGgtaatagcattttcgtcatttcgtta gccttattcaatccatttttgtgaacgtgaatttcccccagGGGTTCAGCTCGACGGTAGCGAATGTATGTGTCCAG ATCATTTTGGTGACGGTGGAAACTTACGGCTACGGCTACTTCGGAACAGATCTAACCACGGAGGTGCTTTGGGtacc ctttqqatqaaqcttcaaaaaqtaattccaaattctqttttcqatttttccccttttccactaqAGCTATGGCGTTG 30 CCCTCGCCATTTACGATAGCGAGTGGTACAAGTTTTCCATTTCGATGCGCCGCAAACTTCGACTGCTACTGCAACGA TCCCAAAAACCGCTCGGCGTAACGGCGGGAAAGTTTCGCTTCGTCAATGTGGCCCAGTTTGGCAAGgtaacattaat tacagtttgaaaattctgaagaatgcatcttacttgccttacttgttgttccagATGCTCAAGATGTCCTATTCATT TTACGTAGTACTGAAGGAGCAGTTTTTAGGAGCTGCTGTTTCCCACCCTGGAAATGGCCTTTTCGCACTGTCTTCTGT TTGTTGGACGCACGCACCGAGAGCGCCCCTGCACGCACTGACGTATTTTGGCTACTTTGACGTTTGCACCTTTG 35 ACAGCTGAAGGACAGGGTACAATTTTTGCTGCTGTTATTACGCGCAGCGCATTGGATACGAAAACATTGGCCACAAG TTCTACGATTTTAGCGTTTATTTACTGTTCGTAGCAGCTTTTTTCCaCATAAACACACACAATAACGTACCGACAG ACGA

Figure 1) - Renvomber figure

Anopheles gambiae odorant receptor 4 genomic sequence (SEQ ID NO: 12)

5

Features:

- 1) Putative Start (ATG) and Stop (TAA) codons are in BOLD.
- 2) Introns are tentatively assigned and are shown in lower case.
- ${\tt GGGGAACTCCCCCACCGACCAGACGACGGAAAGCTAACGATGTGCAATTGAATAGTCATTAGT}$ 10 AGCGTTTTTGCTCGCAAACGAACTAACCCTTTGACTTTTTAAGTTCACTACGGTGAGGACAAAAA AACAACACAAAAATGCATCCTTTCGAATATTAGTCAGGTTGTATCAACAATGAAGTTTGAACTGT 15 TTCAAAAATATTCCTCCCCGGACACGGTCTTATCCTTCGTGCTAAGGCTTTTGCATATCGTGGGC ATGAATGGGGCAGGATTTCGGTCGCGAATTCGAGTTGGTGGCATTTTTCTGTTCTATTTAATCTT TCTTGTAATACCGCCACTAACGGCCGGGTACACCGATGGTCACCAGCGTGTACGCACCAGTGTG GAATTCCTGTTTAATTGCAATATTTACGGCGGCAGTATGTTCTTTGCCTACGATGTGGCCACTTT CCAAGCGTTCATCCAGGAACTGAAGAGCCTTTCGGTTTTGGgtaat at tatta at ta a tata a a ttgcgttt at ttgcat a construction of the constructi20 catcatttgtttctctttgcagTATGCTCACATTCGTACAGACTAAAGTATAAGCTGACCCGGTTCAACCGTCGAGCGGATATTATCGCCAAAGTGCAAACGACCTGCATGGGTGCTGTAACGCTTTTCTACTGGAT TGCACCGATACCTTCCATCTGTGCGCACTACTACAGGTCGACCAATTCCACCGAACCCGTGCGG TTTGTGCAACATTTAGAGGTGAAGTTCTATTGGCTCGAGAATCGCACCTCAGTCGAGGACTACAT 25 TGACCATCTGCTGCAGCATTGGACACTGTACACTGTACACCAGGATGACTATAGAGATGGTAGA GCAGTTGGAAAGCATGGCATCAGCGGAACGAACTGCCAGCGCCATACGCAACGTGGGGCAGAT ${\tt gtttggaaatccaaaaaaaaaaaaaagatggctataattgaactttctattacagGGCATCTCGCTACAATCGGTTACCGTGGT}$ 30 GGTAATGTTTTTTCTTGCCACTGCGGAAACTTTCCTGTATTGTTTACTTGGGACGCGGCTTGCGA CACAACAGCAGCTGCTGGAGCACGCACTCTATGCTACACGGTGGTACAACTACCCAATAGCCTT ${\tt TCGCAGCAGCATTAGGATGATGTTGAGACAGTCGCAAAGGCATGCACATAACGGTGGGGAAG}$ TTTTTTCGCGTTAATTTGGAAGAATTTAGCAGGATTGTCAACTTATCCTACTCTGCTTACGTCGT AGTTTTCCGAATCTATATTAGATCTAGAATTTAATCTAGATGTCATAATATGATCTTGGCCATGA 35 CCGGTTCCTGGTTTTGGAACCAATTCTCAAAACAATTTTGAACTTAGGGCGAGGCATGAAATGTC CCAAGAACCTATCCAAGTTCTGGAACTACATATTACCGAATCTATCCCATTATTGCCTCGGAACT GGTTTGGTGCTAAATATTTGTCCAAATGTTGGTCCTGGACCTATCCAGACAAAGATCTTCAATTA TTCCTACCACTGGAACTGATTAATTGATGTAGGAAGTCATGGAGGTGTTCAGGGAGAATTTAAA 40 CACTAATGTTCCAACTCATTATTTCAAGGGCAATTCTATTTTTATATGCCCCTACGGATTGATAC GTATGTATTACTCCATTTCCTGGACTTTGTCTTATTCTTGCTGCTGATTGGACGTGAAATGTTGA GAAAAGATTCTTATTTATGAGTGATACAGAGCCTTTAAATACTCCTACGTTGTTTGCTATTTAA GTATGGCCAGGCTAATCACAATCGCTACTAATGAACAGAATCTCTTCTAATTAAACCCTTTCGAT TGATAGTGTCAATGTCGAGATAATTGAACTGCAAACgATACCTACCTTAAACGGAGCAG 45 AACACATCAAGAAGCAATTAGGTGTGTCGTACGTTAGCAAGTAGTTCGCGAGGAGGAATAAAAT

50

AG

Figure 5) - Renvomber flgure

ANOPHELES GAMBIAE

Preferred DNA Codons

Amino	Acids				Preferre	d Codons		
Alanine	Ala	A	GCC	GCG	GCT	GCA		
Cysteine	Cys	\mathbf{C}	TGC	TGT				
Aspartic acid	Asp	D	GAC	GAT				
Glutamic acid	Glu	${f E}$	GAG	GAA				:
Phenylalanine	Phe	F	TTC	TTT				
Glycine	Gly	G	GGC	GGT	GGA	GGG		
Histidine	His	H	CAC	CAT				
Isoleucine	Ile	I	ATC	ATT	ATA			
Lysine	Lys	K	AAG	AAA				
Leucine	Leu	L	CTG	CTC	TTG	CTT	CTA	TTA
Methionine	\mathbf{Met}	M	ATG					
Asparagine	Asn	N	AAC	AAT				
Proline	\mathbf{Pro}	P	CCG	CCC	CCA	CCT		
Glutamine	Gln	Q	CAG	CAA				
Arginine	\mathbf{Arg}	R	CGC	CGG	\mathbf{CGT}	CGA	AGA	AGG
Serine	\mathbf{Ser}	S	TCG	AGC	TCC	AGT	TCT	TCA
Threonine	\mathbf{Thr}	T	ACG	ACC	ACT	ACA		
Valine	Val	V	GTG	GTC	GTT	GTA		
Tryptophan	\mathbf{Trp}	W	TGG					
Tyrosine	Tyr	Y	TAC	TAT				

http://www.kazusa.or.jp/codon/cgi-

bin/showcodon.cgi?species=Anopheles+gambiae+[gbinv]

Figure 6)-Renumber figure

X19016-
Delete
L Deig
Comme

Name	SEQ ID NO
Arrestin 1 (cDNA)	SEQ ID NO: 1
Arrestin 1 (polypeptide)	SEQ ID NO: 2
Odorant Receptor 1 (cDNA)	SEQ ID NO: 3
Odorant Receptor 1 (polypeptide)	SEQ ID NO: 4
Odorant Receptor 2 (cDNA)	SEQ ID NO: 5
Odorant Receptor 2 (polypeptide)	SEQ ID NO: 6
Odorant Receptor 3 (cDNA)	SEQ ID NO: 7
Odorant Receptor 3 (polypeptide)	SEQ ID NO: 8
Odorant Receptor 4 (cDNA)	SEQ ID NO: 13
Odorant Receptor 4 (polypeptide)	SEQ ID NO: 14
Odorant Receptor 5 (cDNA)	SEQ ID NO: 15
Odorant Receptor 5 (polypeptide)	SEQ ID NO: 16
Odorant Receptor 6 (cDNA)	SEQ ID NO: 17
Odorant Receptor 6 (polypeptide)	SEQ ID NO: 18
Odorant Receptor 7 (cDNA)	SEQ ID NO: 19
Odorant Receptor 7 (polypeptide)	SEQ ID NO: 20

Figure 7 Remmen figure

Anopheles gambiae odorant receptor 5 genomic sequence (SEQ ID NO: 21)

5

Predicted Exons: *ITALICIZED*, <u>UNDERLINED</u> AND <u>HIGHLIGHTED</u>. Introns: lowercase.

10 tctagacttgaacccatgacgggcattttattgagtcgttcgagttgacgactgtaccacggggaccacccgtttatcactatcactatta atta atta tata at atgett ttg tag cg at cag cct accg gg ttt tg tt tct ctg gat at ctt a ag tt ccc att tg attat ca ag at ag a acceptance of the control ofcaacaacttgtaccttaaataatcattacgtacccttaatcaacctgtgcatcaaggagttttcgcgaaagcaaaaatccgattgtct gatgttgtcttgattccatccgattcgttactggttctgcaaaatcgtccaataatacggcaatgtccttatcgatgcttgaatcaacat cacattgtttgcatttcgtttttttgcgtgcaaatatgttatttgcaaagaaggcaaggtaatgtgcttaagagtaaatacaattcgctg 15 TGCTACCGAAGCTGTCCGAACCGTACGCCGTGATGCCGCTTCTACTACGCCTGCAGCG ĪĪĪĪĒGĪĪĞGGCĪĞĪĞĞĞĞĪĞAACĞACĞCTATCĞCTAĞAĞITCCĞĞTĪĞĞCATTĪTTA AGCTTCTGTCTGCTAGTAGTTATTCCGAAGGTTGCCTTCGGCTATCCAGATTTAGAGAC AATGGTTCGCGGAACAGCTGAGCTGATTTTCGAATGGAACGTACTGTTTGGGATGTTG20 AAAGATTGg ${
m tgcgtgataatgattgataaaaggaacctttgagcaactcctatccctttcaag}{\it CTTTCCGTAAGGAC}$ *CAAGATCTACTGCTGCAGCCATCTGTGTTTGGCCATCTTCTACTGGGTGGCTCCTTC* CCAGCACCTACCTAGCGTACCTGGGGGGCACGAAACAGATCCGTCCCGGTCGAACATGT25 GCTACACCTGGAGGAGGAGCTGTACTGGTTTCACACCCGCGTCTCGCTGGTAGATTAC TCCATATTCACCGCCATCATGCTGCCTACAATCTTTATGCTAGCGTACTTCGGTGGACT*AAAGCTGCTAACCATCTTCAGCAACGTGAAGTACTGTTCGGCAATGCTCAGGCTTGTG* GCGATGAGAATCCAGTTCATGGACCGGCTGGACGAGCGCGAAGCGGAAAAGGAACTGA TCGAAATCATCGTCATGCATCAGAAGGCGCTAAAgtaaggtctgccggtatgttgtggatagaatacattt 30 ctagctgctttcag/ATGTGTGGAGCTGTTGGAAATCATCTTTCGGTGGGTTTTTCTGGGACAG TTCATACAGTGCGTAATGATCTGGTGCAGCTTGGTTCTGTACGTCGCCGTTACGgtaacta aaagcactgtagtgatctgtctgccacaccattcactgctgtgtcttgttttgtcactcttcccag GGTCTCAGCACAAAAG CGGCAAACGTGGGTGTACTGTTTATACTGCTAACAGTGGAAACCTACGGATTCTGCTA CTTTGGCAGTGATCTTACCTCGGAGGCAAGTTGTTATTCGCTGAgtttcagttacttttccgttcccc 35 tctaaccgtaccacttgtaccatttgtttgagacagagcttgagcgtagCACGTGCTGCGTACGCTAGCCTCTGG TATCGCCGTTCGGTTTCGATTCAACGGAAGCTTCGAATGGTACTGCAGCGTGCCCAGA AACCGGTCGGCATCTCGGCTGGGAAGTTTTGCTTCGTCGACATTGAGCAGTTTGGCAATetatggggagaccttccactgtggcaagaaagattttctttattaatgcatcttttaatttacagATGGCAAAAACATCA TACTCGTTCTACATCGTTCTGAAGGATCAATTTTAAaggggaactcccccacccgaccagacgacgaa 40 agctaacgatgtgcaattgaatagtcattagtagcgtttttgctcgcaaacgaactaaccctttgactttttaagttcactacggtgag cataatcataattatatgccacattttattataagtttttg

Figure 8	Renumber	Figure
\bigcirc	1 • -	J

Anopheles gambiae odorant receptor 6 partial genomic sequence (SEQ ID NO: 22)

5 These are the predicted last three exons of another candidate *Anopheles* gambiae odorant receptor.

Predicted Exons: *ITALICIZED*, <u>UNDERLINED</u> AND <u>HIGHLIGHTED</u>. Introns: lowercase.

10

 $ttgatgccgtatgcgccgcgtgctataggctag\underline{\textit{TTATGCTTACCGGATGTTGCGATCGCGCACGTGCTTT}}$ TCCGCATACGCCAGTGCACACTTGATGGCGGTGGTGATGACGTCTGCTGCGCACCGTT 15 ACAGACGGTTAGACGGATATATGCTGGTAAAGTTTGTCCTCTTCATGCTGTGCTTTCTG ATCGAGCTGCTGATGCTGTGTGCGTACGGTGAGGATATTGTGGAATCGg ${f taag}$ gcaccaggc ggtgatgagcgagtcgcgagtaattgaagcttttgcttttaaaacacatcagagCCTTGGGGTGATTGATGCCGCT TACGGTTGCGAATGGTACCGGGAAGGGTCGGTGGCGTTCCATCGATCCGTGCTGCAAA TTATACACCGCAGCCAGCAGTCCGTCATACTGACCGCATGGAAAATTTGGCCCATCCAA 20 $\underline{ATGAGTACTTTCAGTCAG}_{ ext{G}}$ gtgagttgccaattgattgccgtttgcgttaatatttcagtaagagtgcgctctttcccttag ATCCTGCAAGCTTCCTGGTCCTACTTTACCCTCCTGAAGACCGTCTACGGGAATAAgtaa gcgcgagagagagagagagagagtatcgttcaccctttggatgaatcaatagatttctaatcatgaaccattgaaaaatgaatca acattttcgctagttgcacaatattgtaccattctatacagcttcaccacgaccaagcgtttgttgcatcaggaccaaacacgtttcga 25 caagccgcgtcacctgctggc

Figure 9) Renumber figure

Anopheles gambiae odorant receptor 7 genomic sequence (SEQ ID NO: 23)

5

Features

- 1. Predicted Exons (7): ALL CAPS, ITALICIZED, UNDERLINED, HIGHLIGHTED
- 2. Introns (6): lowercase
- 10 3. 5' and 3' sequences: lowercase, dotted underlined

 ${\tt ccgcccgggcaggtgacttacgcggtctgacttgctggtgcgctgctttgtacggcaaacggctacacaagcgaatcgaattattttcc}$ tatcacgetgcgcttaccagcgcctgctggtaggcaaagaatgtgcaaagtttcatttggcttggttcgtctgctttgctgtgaacgtgt 15 gcattgtgtttagtgagaagtgaaaaggaaaagtgctgaaaaatgcaagtccagccgaccaagtacgtcggccttcgttgccgacctgatgccgaacattcgggttgatgcaggccaggggtcaactttctgttccggctacgtcaccggcccgatactgatccgcaaggtgtac tcctggtggacgctcgcccATGGTGCTGATCCAGTTCTTCGCCATCCTCGGCAACCTGGCGACGA ACGCGGACGACGTGAACGAGCTGACCGCCAACACGATCACGACCCTGTTCTTCACGCA 20 CTCGGTCACCAAGTTCATCTACTTTGCGGTCAACTCGGAGAACTTCTACCGGACGCTCGCCATCTGGAACCAGACCAACACGCACCCGCTGTTTGCCGAATCGGACGCCCGGTACC ATTCGATTGCGCTCGCCAAGATGCGGAAGCTGCTGGTGCTGGTGATGGCCACCACCGT CCTGTCGGTTGTCGgtatgtgtgtatgtgtgtggccgtttgggaaagtgtctttgcggcagaaccccaatctactgttacgc ttgactgggtttttgttttttctcggtggagggacgggataaaatatctgaaagaataattgagtcaacccacagggggatgcaag 25 acatcgcaggcagagagtttgggtttgatttatcaccgcacaccgaatatcttcacggttcataagcttcaccgcggtgaaaaggga cctactag CCTGGGTTACGATAACATTTTTCGGCGAGAGCGTCAAGACTGTGCTCGATAAG GCAACCAACGAGACGTACACGGTGGATATACCCCGGCTGCCCATCAAGTCCTGGTATC CGTGGAATGCAATGAGCGGACCGGCGTACATTTTCTCTTTCATCTACCAGGTACGTTG 30 GCGGAA/Igtcctgcgcgtcacagttggcagtcagtgagcggcaacacggcgaaaaaatgggactaaaaccggtcttcacaga gccaacacattcctacagcaattgcataccttcgggcggtcgggactgggcaatgcagctacaacatcctcgcctaaagttatgcaat tcgagcgacaaatgttgccgtgttagggctttttgtgataatagtcgtttttttgtcctctcgcttatcaaactctatcaacggaggaaatccattttcgctacaatgcctacagctcaagtttcaaggtcaatcgagcgggtggggatcaacttttttattcattttgctaacgccccatcaacaaattctatgttctcaatggcaaagattactgcccgcaccaatcgcccaacgaaacggcaaaaggaaaagcgacgattatga 35 agatgtccaaaccattgccgccgacgctttatctgatgatttgcgggatggctttacttgtctgctactttcaggcacaaaaggaa cccgtaacgattaattettttcaaagagattetttcaaagagattcaaaatgtgtataacaaatgctaacgaatggaccgtacttgg 40 gtggcggcagatgtgtcgctgtccgcttccttccttcccagcaagctcgtgcgaaataatttattccatcattttaatacagccgtttgtg cattttaattagcaaagcaatataaaaagcagctaaccatccccattaaaacaaagtgcttccgggcccaattgttatggcggtgga aagtaatggttttaccagtggaagtgtcctttcccatcgtgggtacttcgcgatattcttgtcttatacaagtgcatacagaaaaaaaggacaa at cet cettget at ggtet a aggee agette ggtace gette eggtat get at a a agtt t gat gggt gtt tt taa eatter the state of the stateacttccgctcttaaccacctaatggacttttcatgcttgagctaaagttaaaccagccaccagcggtacgcaccgagccacggttgatt45 tcggcggcggcctcatccccagttttgcgccaccaatattgccttcattaatctgtaccctcggagcgttagggcccgcggacgagtcct

Renumbered fraus tgctacaacacattttatgcttcacagatttacttcctgctgttttcgatggtccagagcaacctcgcggatgtcatgttctgctcctggt) GAGCTTTCGGCCTCGCTGGACACCTACCGGCCCAACTCTTCGCAACTGTTCCGAGCAA 5 TTTCAGCCGGTTCCAAATCGGAGCTGATCATCAACGAAGgtatgtgaaacgtgtgctcgtggcagacg gactcaaagagagcataacacaatcccctggtagttcatttcaatgaccttaacactcggcaagctaagcgagacagtggggacag tgagaaagagagaacaagaaaaaaaccatcatccgtacgacatcatcgctacgtaccggtatttcaggatgaggaaataaaac 10 gagcaaaaaaagtcaaataaattgaagtttaaaaatagattttccccgtccatccgtggtggagcgtaaagcccggcggacaactt cattta at ctatege ge c t g tae ge c ta e tatege a consideration of the consideration of theacgcccgtggtgcccaaagcgcaacgcgaattgcatgttaacaaacctttgcctaccatccaatccgtgtgaaattgcccgctctcttt15 $ctta a {\tt gtc} ca {\tt atgta} a {\tt ttta} c {\tt gtg} t {\tt tctg} t {\tt cgtc} a {\tt cct} t {\tt ctt} c {\tt gtcg} a {\tt tgg} a {\tt gtg} t {\tt gg} c {\tt acgata} a {\tt aaa} a {\tt acccact} t {\tt ctta} a {\tt gtc} a {\tt ctta} a$ gcacgttacggaccgagggaaaggtctttttgtaggcctagcaacggtcctcattcaccgcatgggggtgtagctcagatggtagag 20 cgctcgcttagcatgtgagaggtaccgggatcgatacccggcatctccaacccacacaaaacgtttttaagaagatttttagggaagatattaacgcgggtacactgtgctcctctaagttggaagagtagatgatgatgacaagggagaaggaacatgtgtacgtgttt25 g<u>AAAAGGATCCGGACGTTAAGGACTTTGATCTGAGCGGCATCTACAGCTCGAAGGCGG</u> ACTGGGGCGCCCAGTTCCGTGCGCCGTCGACGCTGCAAACGTTCGACGAGAATGGCAG GAACGGAAATCCGAACGGGCTTACCCGGAAGCAGGAAATGATGGTGCGCAGGGCCATC AAGTACTGGGTCGAGCGCACAAGCACGTTGTACGgtaggtatggtaatttctaaggtgtgtgtaaag 30 ctgaaaccggttgcaatatcgttttgcgaagaaattatgtgtaaagcgtattacaatctcattcctctgttaatctgtaccaattgtgtc agccccgaccgaaagcagcctaattcgtaccagaaaaaccacaagctgtttgtaagcatcgatacgcccgaagctttcaatccagc caaggege cac ctact at tgaegt gaet tttt tge acgt teacact et eccet te te cat tet tt et at aac caateg te get eag ceage at the teacher of the tcgcccggagtgaagtttttatttgaacgatatcacccgtatcgattttccactaaacatgcttaaatcgtttcacaaagctcccccaaa35 gagtaaccgaacaacctcttgccgctgcttcacgatatcgaacagcaccaagataagcatccctttttccctagccgatgtctccgata tetegatteegetteeagegaggeaaagaaaaggegaaetggetgaceteaceeggggegaggaaaaagggtagggattaegte gagcagcacgagttgtgatttcttcttcttcttgttccataaatcgctgacggtttccattaccgcctgcggagtgcacacacgtgaag ggaaagcgaaaacgtttagattccagcagcaacggcagcaccagaagcagcagcagcagcggcaaattgaatcatcctgacgcgat 40 gagttgtctgggttttcgggtcggtggcttacagcaccacaccatctgctgcagctaatacagctgtaaatttcgttagacatagactt gattttacaatattacacacacacattacacacacacattatagatttgtcgcttggcgtatggctctgtacggcgtgccgtacatgccgcgagccgtgttgctgctgctgctgctaccgatcacgtccgattcgattcagcctgcgtgttttttggtgaagatccttatcggtgacccact ttcagtgtgtcgagaggggggggggggcactatggggctgtcagttggaaagctaggctcgattcaaagggccattgtgccagtgttctttttaagatagcgataagcttttgatcgaaatagtaaatcaaacattgtttcttttttcctattccaaactgttgccaacctcattattacg 45 tttttgcagcgggtgtatagtaaattgcatactttaaggcgtgattttcaaatgtagcgttccgtatgcagaaacgccatggattatgca att taa acaat get get teet taa catte aaataa egget tatta aggaa ett ttt gt geaat tt gt tt ttaa cagea aatag tt ageaat get get get generalise gtcagaacgatcacatttagtatcgcttcaacaaagaactcttttaaacacacaatttgtaatgccattccctcgagaaagtttcttgtcagtectectetgeateacageaacaaccaaacctgeteatgttteetgetegttteetagetgttttgaacgttattteegatteetgtget

Renumbered tgcccgcttttcttacaatcaaccacaatggttcagatttcgctcttattttattgacccactgctttcgtgctgaagcccgtggaaacaa tgcgccaagctcagcatccagccatgcatgtaaaatgagccacgcgacagattttagacatcgctttcgctctgcaccggaggtggttaacgagccagaaaatgagcacgccaaatgcaaagaaaatccccttttgagtggtgctcctgccaccactcatctccccaactggtgg 5 cgcagaagctcaaaccaacgccgccagcaagcatcaacaatttctattcaaacacccaacgcagcgcccaaaccgggtgcactgta ctcagtagcgaagatgctcagattgtcccgtgcgctgctttcgatgcccgtttcggagcgggaagccatcgcttgccaacgttggcgat ccgtaccgcggtggggcgagttttcaacgcaaccttctacaagcaacgccacaacgcctgggagcgatatttaacagaaacaagaa10 catecegaacttcageacatgeegtgatttgeetgttggaaaagettttgtgagegtgtgagttgaaegagetetatttteeeagegat gggtggcattttgtgtggcatgctatcgtcagcttttcttgaatctttacctctccattcgcctccattagtacacgcgtatggaaaatgg gtgcaacggatcagaacggattttccgcgacagacttaataaagggaaagcaacgcgttttttgcatgtgtagtgtttatgagcttt 15 aaaaaaatgtcaatctgtatcgattattcacacaaatcagatcccggaaccagtgtagcccaatgtgctcttattgaattaccacga acaaatcaacctgatgcccgggtccgttggcaaacagcttgcgccgaagccgctcagtgtttcgtgcactaccgtgctgccattttgct gccctcatcgaacagataaacagaagggcaactcttgtgagcatcgcaatgcccgtctgaagttccgtcgaaaatgggcctaaattc 20 aaatgttategttteggeatgttteteggtacaaagegtgtggegetatgtggcatgeegatteeeagacagagtgategatagtaaa tttgggattggtttttgcagcgaaaaatcaaaacattcgcacaaaaccgtcctccatttcaaatgcctacacttgtcactgtatatctct 25 ${\tt ctttctctcgttttgccacgttgcag} \underline{{\it TCTCGTTTCAGCAATCGGAGATACGTACGGTCCTGCCCTGCT}}$ GCTACACATGCTGACCTCCACCATCAAGCTGACGCTGCTCGCCTACCAGGCAACGAAA <u>ATCGACGGTGTCAACGTGTACGGATTGACCGTAATCGGATATTTGTGCTACGCGTTGG</u> CTCAGGTTTTCCTGTTTTGCATCTTTGGCAATCGGCTCATCGAGGAGgtacgtgcgctcggcgtg ttgccgtgggaaagcattctccctgccccatatcgcttcattctcccagatcacacatttgcatcacaaagccagcacacttttgcttcg30 ccgctgccatctcggcttctgaatgttttcacttctcccatacttctcccgtgcag/AGCTCATCCGTGATGAAGGCGGC CTATTCCTGCCACTGGTACGACGGGTCCGAGGGGGGGCAAAAACCTTCGTCCAGATCGTT TGTCAGCAGTGCCAGAAGGCGATGACTATTTCCGGAGCCAAGTTTTTCACCGTTTCGC TCGATCTGTTTGCTTCCgtaagtgtagcctggtggctggcacaggactggcaaaacagggactttggctctagc 35 CTACTTCATGGTGCTGCAGCTGAAGTAAacagccgtggcccggaaggatgtgttttttttcgctcgttcg acagatetttgcaaaatgattagattttaatagattaacagtgettgattatetgteetgtageaaceggggetgaagaacgttgatt tggtaaaagtacaaaagggacgttggaaattgaaccaccagaagagtgatatttatgcaaagctcaccaagggaaatctatgtatgtgtgatttgcgctcatcaagcactgtatgtgcctttcaactagtgcagcaataaagagtacaaatgtttcttagcgcaccgtacattg 40 ctt caa acateget teaa aag tattactacea cattatte atttact tatatg tatatt tattgeet et teatet teete categee agaaet attender on the control of the45 ttcgcatcgagatggaaatgaatgtaccactagaaccgagtgaaatgaattacttttcaacttgcacgccaaaaccattatctaaag agaaaaaaaaaaaaacacttccacgggaagctagcaattggaaatgcataaattaaccggaagaaattcgcaaaaccccgcaccgac

5

Figure 9 continued

Renumbered figure

Figure 1 This original figure
is cancelled

Anopheles gambiae arrestin 1 cDNA sequence (SEQ ID NO: 1)

5 ACAGGAACGACGGTTGTGATCCCTCCACTGGTGGTGACACGAATCATAAGCATTATTTCATACCT AAAAAACAAAATCTACAAAAAAAAGCTTCATTCCCATCGAAAAAACTTTCTTGTGAAATCAACCG AGCTAACAACAACATCCTGTGCAAAATCTAGCAGTGAAAGTGTGATATCGTATACCTGTACCTG TAAACCGTTGTGCGCGTGTGTGCCTTTGTGTATCAATTTTGTGGAAAACAGAAAATACATCAAAA 10 <u>TG</u>GTTTACAATTTCAAAGTCTTCAAGAAGTGCGCCCCTAATGGAAAGGTTACGCTGTACATGGG GATGAGTACATTCGTGACAACCGTAAGGTATTCGGTCAGATTGTCTGCAGTTTCCGCTACGGCC GCGAAGAGGACGAGGTGATGGGACTAAACTTCCAGAAGGAGTTATGCCTCGCTTCCGAACAGAT CTACCCGCGTCCGGAAAAGTCGGACAAGGAGCAGACCAAGCTCCAGGAGCGACTGCTGAAGAA GCTGGGTTCGAACGCCATCCCGTTCACGTTCAACATCTCGCCGAATGCTCCGTCTTCGGTCACG 15 CTGCAGCAGGCGAAGATGATAATGGAGACCCGTGCGGTGTGTCGTACTACGTGAAGATCTTTG CCGGTGAGTCGGAAACCGATCGTACGCACCGTCGCAGCACCGTTACGCTCGGCATACGCAAGAT CCAGTTCGCACCGACCAAGCAGGGCCAGCAGCCGTGCACGCTGGTGCGCAAGGACTTTATGCTA AGCCCGGGAGAGCTGGAGCTCGAGGTCACACTAGACAAGCAGCTGTACCTGCACGGGGAGCGA 20 ATAGGCGTCAACATCTGCATCCGCAACAACTCGAACAAATGGTCAAGAAGATTAAGGCCATGG TCCAGCAGGGTGTGGATGTGGTGCTGTTCCAGAATGGTAGCTACCGCAACACAGTGGCATCGCT GGAGACTAGCGAGGGTTGCCCAATTCAGCCCGGCTCCAGTCTGCAGAAGGTAATGTACCTCACG ATCAGTGTTTGGCCTCGACAACCCTCTTGGCTCAACCGGATCAGCGAGATGCTTTCGGCGTTAT 25 CATATCGTATGCCGTAAAGGTTAAGCTTTTCCTCGGCGCGCACTCGGCGGCGAGCTGTCGGCGGAA CTTCCATTTGTGCTGATGCACCCAAAGCCCGGCACCAAGGCTAAGGTCATCCATGCCGACAGCC AGGCCGACGTAGAAACTTTCCGACAGGATACAATCGACCAGCAGGCATCAGTTGACTTTGAATA TACTACTACTAAGCATAAAAAACAGGAAAAAAATGGAAAACTTAAAAAATGGATCATACAACCG 30 AACGCAAACGACCTACGACGATCGATCTCACTTCCCCGTCTTTTTCATCCTAAGCAATAGAACGA TGGTAGAAAAGGAAGATAAAGATGGAGAGAAAGTCACGTGTATCAATGACGACGACTACCAAAA CAATGTACCTTTTAAAAACATACAAATTAGAAGTCGTCTTCACTACCTTCAACCAATCCAGCCAC TTTGGTATATACTTTTCATAGAATCCTTCTGAGCGCAAGGACCCTATTGAAATTCAGTGTTATTTT 35 GTAACTGCGACCAAATGCCTAGCTGAATGTTGTTGAACGAGTTATGTACATCAAAAGATTGAATA AAACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

Figure 2 This of ignal figure

Anopheles gambiae arrestin 1 amino acid sequence (SEQ ID NO: 2)

5

10

MVYNFKVFKKCAPNGKVTLYMGKRDFVDHVSGVEPIDGIVVLDDEYIRDNRKVFGQIVCSFRYGR EEDEVMGLNFQKELCLASEQIYPRPEKSDKEQTKLQERLLKKLGSNAIPFTFNISPNAPSSVTLQQG EDDNGDPCGVSYYVKIFAGESETDRTHRRSTVTLGIRKIQFAPTKQGQQPCTLVRKDFMLSPGELE LEVTLDKQLYLHGERIGVNICIRNNSNKMVKKIKAMVQQGVDVVLFQNGSYRNTVASLETSEGCPI QPGSSLQKVMYLTPLLSSNKQRRGIALDGQIKRQDQCLASTTLLAQPDQRDAFGVIISYAVKVKLFL GALGGELSAELPFVLMHPKPGTKAKVIHADSQADVETFRQDTIDQQASVDFE

Figure 3b

Figure 3b

Anopheles gambiae odorant receptor 1 amino acid sequence (SEQ ID NO: 4)

5 ${\tt MKKDSFFKMLNKHRWILCLWPPEDTDQATRNRYIAYGWALRIMFLHLYALTQALYFKDVKDIND}$ IANALFVLMTQVTLIYKLEKFNYNIARIQACLRKLNCTLYHPKQREEFSPVLQSMSGVFWLMIFLM FVAIFTIIMWVMSPAFDNERRLPVPAWFPVDYHHSDIVYGVLFLYQTIGIVMSATYNFSTDTMFSG LMLHINGQIVRLGSMVKKLGHDVPPERQLVATDAEWKEMRKRIDHHSKVYGTMYAKVTECVLFHKDILRIYLRASMRVCNYHLYDTAATTGGDVTMADLLGCGVYLLVKTSQVFIFCYVGNEISYTDKF 10 TEFVGFSNYFKFDKRTSQAMIFFLQMTLKDVHIKVGSVLKVTLNLHTFLQIMKLSYSYLAVLQSM **ESEZ**

Appl. No. 10/056,405 Annotated Marked-Up Drawing This original figure

Anopheles gambiae odorant receptor 2 amino acid sequence (SEQ ID NO: 6)

5 MLIEECPIIGVNVRVWLFWSYLRRPRLSRFLVGCIPVAVLNVFQFLKLYSSWGDMSELIINGYFTV LYFNLVLRTSFLVINRRKFETFFEGVAAEYALLEKNDDIRPVLERYTRGRMLSISNLWLGAFISA CFVTYPLFVPGRGLPYGVTIPGVDVLATPTYQVVFVLQVYLTFPACCMYIPFTSFYATCTLFALVQIAALKQRLGRLGRHSGTMASTGHSAGTLFAELKECLKYHKQIIQYVHDLNSLVTHLCLLEFLSFGM 10 MLCALLFLLSISNQLAQMIMIGSYIFMILSQMFAFYWHANEVLEASLGIGDAIYNGAWPDFEEPIR KRLILIIARAQPTDGGKIKVGNVYPMTLEMFQKLLNVSYSYFTLLRRVYN

Figure 5b

This original figure

Anopheles gambiae odorant receptor 3 amino acid sequence (SEQ ID NO: 8)

5 MPSERLRLITSFGTPQDKRTMVLPKLKDETAVMPFLLQIQTIAGLWGDRSQRYRFYLIFSYFCAMV VLPKVLFGYPDLEVAVRGTAELMFESNAFFGMLMFSFQRDNYERLVHQLQDLAALVLQDLPTEL GEYLISVNRRVDRFSKIYCCCHFSMATFFWFMPVWTTYSAYFAVRNSTEPVEHVLHLEEELYFLN IRTSMAHYTFYVAIMWPTIYTLGFTGGTKLLTIFSNVKYCSAMLKLVALRIHCLARVAQDRAEKEL NEIISMHQRVLNCVFLLETTFRWVFFVQFIQCTMIWCSLILYIAVTGFSSTVANVCVQIILVTVETY 10 GYGYFGTDLTTEVLWSYGVALAIYDSEWYKFSISMRRKLRLLLQRSQKPLGVTAGKFRFVNVAQF GKMLKMSYSFYVVLKEQF

Figure 6b

Figure 6b

Cancelled

Anopheles gambiae odorant receptor 4 amino acid sequence (SEQ ID NO: 14)

MKFELFQKYSSPDTVLSFVLRLLHIVGMNGAGFRSRIRVGGIFLFYLIFLVIPPLTGGYTDGHQRVR TSVEFLFNCNIYGGSMFFAYDVATFQAFIQELKSLSVLVCSHSYRLKYKLTRFNRRADIIAKVQTTC MGAVTLFYWIAPIPSICAHYYRSTNSTEPVRFVQHLEVKFYWLENRTSVEDYITFVLIMLPVVVMC 10 GYVCNLKVMTICCSIGHCTLYTRMTIEMVEQLESMASAERTASAIRNVGQMHSGLLKCIRLLNTSI RSMLMLQWLTCVLNWSISLIYLTNVGISLQSVTVVVMFFLATAETFLYCLLGTRLATQQQLLEHALYATRWYNYPIAFRSSIRMMLRQSQRHAHITVGKFFRVNLEEFSRIVNLSYSAYVVLKDVIKMDVQ NVSYSYFTLLRRVYN

Figure 9b

This original figure Anopheles gambiae odorant receptor 5 amino acid sequence (SEQ ID NO: 16)

5 MVLPKLSEPYAVMPLLLRLQRFVGLWGERRYRYKFRLAFLSFCLLVVIPKVAFGYPDLE TMVRGTAELIFEWNVLFGMLLFSLKLDDYDDLVYRYKDISKIAFRKDVPSQMGDYLVRI NHRIDRFSKIYCCSHLCLAIFYWVAPSSSTYLAYLGARNRSVPVEHVLHLEEELYWFHTR VSLVDYSIFTAIMLPTIFMLAYFGGLKLLTIFSNVKYCSAMLRLVAMRIQFMDRLDEREA EKELIEIIVMHQKALKCVELLEIIFRWVFLGQFIQCVMIWCSLVLYVAVTGLSTKAANVG 10 VLFILLTVETYGFCYFGSDLTSEASCYSLTRAAYGSLWYRRSVSIQRKLRMVLQRAQKP VGISAGKFCFVDIEQFGNMAKTSYSFYIVLKDQF

Figure 10b This original figure

Anopheles gambiae odorant receptor 6 partial amino acid sequence
(SEQ ID NO: 18)

5

LCLPDVAIAHVLFRIRQCTLDGGGDDVCCAPFSARESDLFISCNILFLSRPHRRLDGYML VKFVLFMLCFLIELLMLCAYGEDIVESPWGDZCRLRLRMVPGRVGGVPSIRAANYTPOP AVRHTDRMENLAHPNEYFQSDPASFLVLLYPPEDRLRE

Figure 11b This ociginal figure.

7 amino acid sequence (SEO ID NO. Anopheles gambiae odorant receptor 7 amino acid sequence (SEQ ID NO: 20)

5 MVLIQFFAILGNLATNADDVNELTANTITTLFFTHSVTKFIYFAVNSENFYRTLAIWNQT NTHPLFAESDARYHSIALAKMRKLLVLVMATTVLSVVAWVTITFFGESVKTVLDKATN ETYTVDIPRLPIKSWYPWNAMSGPAYIFSFIYQVRWRNGIMRSLMELSASLDTYRPNSSO LFRAISAGSKSELIINEEKDPDVKDFDLSGIYSSKADWGAQFRAPSTLQTFDENGRNGNP NGLTRKQEMMVRSAIKYWVERHKHVVRLVSAIGDTYGPALLLHMLTSTIKLTLLAYQA 10 TKIDGVNVYGLTVIGYLCYALAQVFLFCIFGNRLIEESSSVMKAAYSCHWYDGSEEAKT FVQIVCQQCQKAMTISGAKFFTVSLDLFASVLGAVVTYFMVLVQLK

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

□ BLACK BORDERS
□ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
□ FADED TEXT OR DRAWING
□ BLURRED OR ILLEGIBLE TEXT OR DRAWING
□ SKEWED/SLANTED IMAGES
□ COLOR OR BLACK AND WHITE PHOTOGRAPHS
□ GRAY SCALE DOCUMENTS
□ LINES OR MARKS ON ORIGINAL DOCUMENT
□ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

IMAGES ARE BEST AVAILABLE COPY.

☐ OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.